Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized, dose-escalation trial in patients with advanced solid
tumors. The trial comprises 2 stages: a dose escalation stage at 8 dose levels of 2, 5, 10,
20, 40, 60, 80, and 100 mg/day,and possibly additional intermediate doses, to determine the
MTD and recommended dose, and a subsequent 2 parts of expansion stage to investigate the
safety profile and antitumor effect of OPB-51602 at the recommended dose.